NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced that its management team will participate in the Sidoti Small-Cap Virtual Conference being held on September 18-19, 2024.
Presentation Details
Date: Thursday, September 19, 2024
Time: 2:30 p.m. Eastern Time
Registration/Webcast Link
For more information about the conference, or to schedule a one-on-one meeting with the INBS management team, please contact your Sidoti representative or email KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Company Contact:
Intelligent Bio Solutions Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.70 |
Daily Change: | -0.08 -4.49 |
Daily Volume: | 257,049 |
Market Cap: | US$8.180M |
June 11, 2025 May 13, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load